CAMBRIDGE, Mass., Jan. 7, 2022 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today ...
Nuvalent's NVL-655 received FDA Breakthrough Therapy Designation for ALK+ NSCLC, showing potential as a vital therapy. Nuvalent's pipeline includes innovative kinase therapies for NSCLC, with NVL-655 ...
CAMBRIDGE, Mass., Sept. 18, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase ...
Nuvalent, Inc. stock gained 36% and reached an all-time high of $58 per share yesterday, with a market cap valuation of $3.3bn. The biotech company is focused on developing targeted therapies for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results